Navigation Links
Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
Date:4/15/2013

FREMONT, Calif., April 15, 2013 /PRNewswire/ -- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today the appointment of Kleanthis G. Xanthopoulos , Ph.D., to its Board of Directors. Dr. Xanthopoulos is President & Chief Executive Officer of Regulus Therapeutics Inc. (NASDAQ: RGLS), a leading company developing microRNA therapeutics.

"I am pleased to welcome Dr. Xanthopoulos as our independent board member," said Vikram Lamba, Chief Executive Officer of Zosano Pharma. "He is a veteran life sciences industry CEO whose extensive healthcare, execution and IPO experience will provide Zosano with valuable insight as we pursue potential public options for financing our extensive clinical development program."

Prior to joining Regulus in 2007, Dr. Xanthopoulos was a managing director of Enterprise Partners Venture Capital. He co-founded and served as President and Chief Executive Officer of Anadys Pharmaceuticals, and remained a Director until its acquisition by Roche. He was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals), and participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute. Previously, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden after completing a Postdoctoral Research Fellowship at The Rockefeller University, New York. An Onassis Foundation scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden. Dr. Xanthopoulos is a member of the Board of Directors of the Biotechnology Industry Organization (BIO), Apricus Biosciences, Sente Inc., and a member of the board of BIOCOM, Southern California's life science industry association.

"I am delighted to join the Zosano Board," said Dr. Xanthopoulos. "Zosano's ZP Patch Technology has the potential to provide novel drug delivery solutions for many therapeutic indications – and I look forward to working with the other Board members and management team to shape the company's future."

About Zosano Pharma

Zosano Pharma, Inc. is a private biopharmaceutical company and a pioneer in the field of drug delivery systems. Zosano is developing products using ZP Patch Technology, a novel transdermal delivery technology based on microprojections that provide rapid and efficient systemic delivery in a convenient, needle–free, and pain–free system. Zosano is a fully integrated development company with a recently launched cGMP manufacturing capability. The company is developing products with significant commercial potential both independently and in collaboration with strategic partners. Learn more at http://www.zosanopharma.com.

 

 

 


'/>"/>
SOURCE Zosano Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zosano Pharma, Inc. Announces Key Strategic Hire
2. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
3. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
4. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
5. InnoPharma, Inc., Announces U.S. FDA Approval of Acetylcysteine Solution, USP, 20% for Inhalation or Oral Administration
6. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
7. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
8. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
9. DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
10. As Smartphone Usage Expands, Survey Says Nurses and Nursing Students Want Mobile Access to Credible Drug Data
11. BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... July 11, 2017  The global market for liquid ... approximately $394.1 million in 2016.  Although in early stages, ... growth, in particular as a result of the gradual ... the recent introduction of a significant number of new ... testing of tumor biomarkers to guide treatment decisions. ...
(Date:7/10/2017)... CLEVELAND , July 10, 2017  US medical ... billion in 2021, according to Medical Equipment ... released by Freedonia Focus Reports. Continued increases in demand ... the aging of the population and supported by gains ... associated equipment and supplies. New product introductions will also ...
(Date:7/10/2017)... TRIANGLE PARK, N.C. , July 10, 2017 /PRNewswire/ ... a $5m Convertible Note to support the development of ... by Tencent Holdings Limited, a leading Chinese Internet services ... This funding will advance multiple infectious disease product programs ... Founded by Dr. ...
Breaking Medicine Technology:
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Cheerag ... Saint Luke’s Marion Bloch Neuroscience Institute (SLMBNI), part of Saint Luke’s ... since 2016. , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins Stanley P. ...
(Date:7/24/2017)... ... July 24, 2017 , ... Horizon Goodwill Industries, ... unique opportunity that helps high school girls succeed in STEM programs as well ... Horizon Goodwill will host over 20 high school girls at their corporate headquarters ...
(Date:7/24/2017)... ... ... Every year, thousands of dedicated Higher Education and K12 professionals flock to ... with a dynamic theme like Camp Canvas; this year, they’ve managed to take it ... To extend their partnership with Canvas beyond the LMS integration, Modo Labs secured the ...
(Date:7/24/2017)... ... , ... A CDC study shows that, although people are taking more steps to protect themselves ... at least one case of sunburn within the past year. It’s common and people have ... issue. However, only recently have people become conscientious of the risks that accompany sunburns. , ...
(Date:7/24/2017)... ... July 24, 2017 , ... Sharon Kleyne, host of the nationally syndicated ... VoiceAmerica sponsored by Nature’s Tears® EyeMist® recently talked on the air about an alarming ... , The article by Zidor Aldama described the situation in which Chinese children are ...
Breaking Medicine News(10 mins):